Determination of trimetazidine HCl by adsorptive stripping square-wave voltammetry at a glassy carbon electrode.

The adsorptive and electrochemical behavior of trimetazidine hydrochloride on a glassy carbon electrode were investigated in acetate buffer solution by using cyclic and square-wave voltammetry. Cyclic voltammetric studies indicated the oxidation of trimetazidine hydrochloride at the electrode surface through a single two-electron irreversible step and fundamentally controlled by adsorption. The solution condition and instrumental parameters were optimized for the determination of the authentic drug using adsorptive square wave stripping voltammetry. Trimetazidine hydrochloride gave a sensitive adsorptive oxidative peak at 0.750 V (vs. Ag/AgCl). The oxidation peak was used to determine authentic trimetazidine hydrochloride concentration in the range 5.0 x 10(-8)-5.0 x 10(-6) M with a detection limit of 2.0 x 10(-8) M. The procedure was successfully applied for assay of trimetazidine hydrochloride in the tablet dosage form (Vastarel). A mean recovery of 94.7% with a relative standard deviation (R.S.D.) of 0.88% was obtained. Applicability to assay the drug in urine samples was illustrated. The peak current was linear with the drug concentration in the range 17-85 microg per ml urine. The detection limit was 1.7 microg ml(-1) urine.

The metabolism and excretion of trimethadione in patients with percutaneous transhepatic biliary drainage and renal dysfunction.

The metabolism and excretion of trimethadione (TMO) following an oral dose of 4 mg/kg has been examined in patients with percutaneous transhepatic biliary drainage (PTBD) and renal dysfunction. Biliary excretion as the total amount of TMO and its metabolite, dimethadione (DMO) was 2.0% of the dose during 0 to 48 h after TMO administration in patients with PTBD. Total urinary excretion (0-48 h) was 2.8% and 3.0% of the dose in healthy volunteers and patients with renal dysfunction, respectively. The serum DMO/TMO ratio at 4 h after oral dosing in patients of PTBD and renal dysfunction was not significantly changed in comparison with the ratio reported previously in healthy volunteers. The elimination half-life of TMO was also not altered in patients with PTBD in comparison with that reported previously in volunteers. These results suggest that metabolism and urinary and biliary excretion of TMO are not changed in patients with PTBD and renal dysfunction.

Studies on the trimethadione metabolism as a tool for the assessment of drug-metabolizing capacity using plasma and urine of rats pretreated with phenobarbital and 3-methylcholanthrene.

To determine whether concentrations of trimethadione (TMO) and its metabolite 5,5-dimethyl-2,4-oxazolidinedione (DMO) in plasma as well as in urine of rats are useful indicator of drug-metabolizing capacity or not, the following experiments were carried out. Plasma TMO and DMO concentrations were measured in phenobarbital (PB) or 3-methylcholanthrene (3-MC)-pretreated rats following the administration of TMO. In PB-pretreated rats, there was a good correlation between elimination rate constant (Kel and plasma DMO/TMO ratio; r = 0.991 at 1 h, r = 0.967 at 2 h). However, there was no good correlation in 3-MC-pretreated rats (r = 0.780 at 1 h, r = 0.720 at 2 h). TMO and DMO excretion in PB and 3-MC pretreated rats following the administration of TMO were not significantly different in 24-h urine. These experiments, together with the previous findings, indicate that concentrations of TMO and DMO in plasma, but not in urine, in PB-pretreated rats may be a useful indicator of drug-metabolizing capacity.